Evaluating the Utility of a ‘N-of-1' Precision Cancer Medicine Strategy: The Case for ‘Time-to-Subsequent-Disease Progression'

It is increasingly recognized that cancer is a highly heterogeneous group of illnesses even within a particular organ site (e.g., breast, lung, colon, etc.). This observation presents a serious challe